Rose is an associate editorial director at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
CAR T-Cell Therapy in Hematological Cancers: Current Challenges and Future Potential
March 6th 2022Although chimeric antigen receptor (CAR) T-cell treatments have shown efficacy in certain cancers, targeting multiple antigens and overcoming production limitations may advance the field and make this therapy more effective and accessible.
With Natural Killer Cell Immunotherapy, Alloreactive Cell Dose May Be Predictive of Response
February 26th 2022Research has shown that adoptive immunotherapy using natural killer cells may be beneficial in leukemia treatment. The follow-up to a recent study found that the dose of alloreactive natural killer cells matters for treatment response.
Review Finds Sildenafil Safe, Effective for PAH Treatment in Asian Adults
February 25th 2022Studies focused on Asian populations with pulmonary arterial hypertension (PAH) treated with sildenafil are rare, and a new meta-analysis has found the phosphodiesterase-5 inhibitor effective in this understudied subgroup.
Bone Marrow Fibrosis Holds Potential as Independent Prognostic Factor in MDS
February 19th 2022Myelodysplastic syndrome has a variety of clinical presentations, including bone marrow fibrosis. Previously, the presence of fibrosis has not been considered in disease risk scoring in MDS, but recent research suggests it may be a valuable risk factor.
Sleep Apnea in Pregnancy May Up Risk of Metabolic Disease, Hypertension Post Partum
February 19th 2022A study published in American Journal of Respiratory and Critical Care Medicine found that sleep disordered breathing in pregnancy led to a higher risk of both metabolic disease and hypertension up to 7 years post partum.
Metabolic Differences Between Endothelial Cells in PH Phenotypes Explained
February 18th 2022This new study aimed to identify metabolic differences in endothelial cells in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (PH) to aid in the development of novel therapeutic approaches.
IO-TKI Combinations Have Potential as Preferred First-line mRCC Therapy
February 12th 2022Metastatic renal cell carcinoma (mRCC) has seen increased treatment options in recent years, including immunotherapy (IO) combinations paired with tyrosine kinase inhibitors (TKI). A meta-analysis of phase 3 trials aimed to compare and rank available first-line treatments.
Routine Lung CT Reports Have Diagnostic and Prognostic Utility in Pulmonary Hypertension Subtypes
February 5th 2022Idiopathic pulmonary arterial hypertension and pulmonary hypertension due to chronic lung disease can be difficult to differentiate, but new research suggests descriptions of lung parenchyma in routine CT scans may prove useful.
Study Assesses Real-world Outcomes of Immunotherapy in Patients With HCC, Comorbidities
February 3rd 2022A poster presentation from the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium suggests more research is needed to confirm the optimal treatment algorithms for patients with hepatocellular carcinoma.
Study Using Novel Index Links OSA Severity to Higher Cardiovascular Disease Risk
January 29th 2022Patients in upper quartiles of the sleep breathing impairment index, a novel gauge of obstructive sleep apnea (OSA) severity, had higher 10-year Framingham cardiovascular risk than patients whose symptoms were classified as less severe.
Severe Daytime Sleepiness Linked With Parkinsonian-Like Symptoms, Study Finds
January 22nd 2022The severity of excessive daytime sleepiness correlated with the prevalence of Parkinsonian-like symptoms in adults aged 50 to 64, but further research is needed to determine the mechanisms behind the findings.
Understanding Real-World Trends in MRD Testing as Part of MM Management
January 18th 2022An abstract presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition assessed real-world data on patients with multiple myeloma to provide insight into longitudinal testing patterns and rates of sustained minimal residual disease (MRD) negativity.